XORTX receives Japanese patent allowance for XRx-101 program
XRTX•XORTX Therapeutics received a decision to grant a Japanese patent for its XRx-101 program, with protection expected through March 15, 2041, subject to registration and annuity payments.
1. Japanese patent allowance
The patent would provide XRx-101’s first protection in Japan and cover compositions targeting acute kidney injury associated with viral infections. Issuance remains subject to registration, and the expected protection period excludes any potential patent term extension.
